- Home
- GYRE vs GDEN Comparison
GYRE vs GDEN Comparison
Compare GYRE & GDEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- GDEN
- Stock Information
- Founded
- GYRE 2002
- GDEN 1998
- Country
- GYRE United States
- GDEN United States
- Employees
- GYRE N/A
- GDEN N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- GDEN Services-Misc. Amusement & Recreation
- Sector
- GYRE Health Care
- GDEN Consumer Discretionary
- Exchange
- GYRE Nasdaq
- GDEN Nasdaq
- Market Cap
- GYRE 755.7M
- GDEN 642.7M
- IPO Year
- GYRE N/A
- GDEN 1999
- Fundamental
- Price
- GYRE $8.19
- GDEN $29.71
- Analyst Decision
- GYRE Strong Buy
- GDEN Hold
- Analyst Count
- GYRE 2
- GDEN 6
- Target Price
- GYRE $17.00
- GDEN $32.20
- AVG Volume (30 Days)
- GYRE 60.0K
- GDEN 531.4K
- Earning Date
- GYRE 11-07-2025
- GDEN 11-06-2025
- Dividend Yield
- GYRE N/A
- GDEN 3.36%
- EPS Growth
- GYRE N/A
- GDEN N/A
- EPS
- GYRE 0.04
- GDEN 0.20
- Revenue
- GYRE $107,265,000.00
- GDEN $643,485,000.00
- Revenue This Year
- GYRE $15.25
- GDEN N/A
- Revenue Next Year
- GYRE $33.14
- GDEN $2.15
- P/E Ratio
- GYRE $211.54
- GDEN $145.90
- Revenue Growth
- GYRE 2.13
- GDEN N/A
- 52 Week Low
- GYRE $6.11
- GDEN $19.57
- 52 Week High
- GYRE $19.00
- GDEN $35.49
- Technical
- Relative Strength Index (RSI)
- GYRE 59.01
- GDEN 77.41
- Support Level
- GYRE $7.12
- GDEN $28.25
- Resistance Level
- GYRE $7.42
- GDEN $30.20
- Average True Range (ATR)
- GYRE 0.34
- GDEN 0.89
- MACD
- GYRE 0.04
- GDEN 1.09
- Stochastic Oscillator
- GYRE 94.82
- GDEN 95.58
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About GDEN Golden Entertainment Inc.
Golden Entertainment Inc is a U.S. based company that focuses on distributed gaming, casino, and resort operations. Its reportable segments are Nevada Casino Resorts, Nevada Locals Casinos, Nevada Taverns, and Distributed Gaming. The majority of the revenue for the company is generated from its Nevada Casino Resorts segment which is comprised of destination casino resort properties offering a variety of food and beverage outlets, entertainment venues, and other amenities.